Scarica l'app Stockscreener
34.98
3.68%
1.24
Dopo l'orario di chiusura:
34.98
Precedente Chiudi:
$33.74
Aprire:
$33.75
Volume 24 ore:
322.82K
Relative Volume:
0.48
Capitalizzazione di mercato:
$1.13B
Reddito:
$4.85M
Utile/perdita netta:
$-114.75M
Rapporto P/E:
-10.76
EPS:
-3.25
Flusso di cassa netto:
$-100.36M
1 W Prestazione:
+6.26%
1M Prestazione:
-11.11%
6M Prestazione:
+60.09%
1 anno Prestazione:
+25.56%
Intervallo 1D:
$33.43
$35.26
Intervallo di 1 settimana:
$32.89
$35.26
Portata 52W:
$13.37
$40.16
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
34.98 | 1.34B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Using Python tools to backtest Dianthus Therapeutics Inc. strategiesEntry Point & Low Risk High Win Rate Picks - newser.com
Trend analysis for Dianthus Therapeutics Inc. this weekNew Guidance & Accurate Buy Signal Notifications - newser.com
Will Dianthus Therapeutics Inc. stock see PE expansionJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - newser.com
What recovery options are there for Dianthus Therapeutics Inc.Weekly Stock Recap & Free Community Consensus Stock Picks - newser.com
How to escape a deep drawdown in Dianthus Therapeutics Inc.Weekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Long term hold vs stop loss in Dianthus Therapeutics Inc.2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
Dianthus Therapeutics Inc. stock chart pattern explainedMarket Risk Report & Community Trade Idea Sharing Platform - newser.com
Using Bollinger Bands to evaluate Dianthus Therapeutics Inc.July 2025 Review & AI Optimized Trade Strategies - newser.com
Will Dianthus Therapeutics Inc. (87E) stock outperform value peers2025 Year in Review & Fast Entry High Yield Stock Tips - newser.com
Is Dianthus Therapeutics Inc. (87E) stock a fit for income portfoliosGold Moves & High Accuracy Investment Signals - newser.com
Smart tools for monitoring Dianthus Therapeutics Inc.’s price actionWeekly Investment Summary & Low Risk Entry Point Guides - newser.com
Will Dianthus Therapeutics Inc. (87E) stock hit Wall Street targetsWeekly Earnings Recap & AI Driven Stock Price Forecasts - newser.com
Can Dianthus Therapeutics Inc. stock hit analyst price targetsWeekly Gains Report & Verified Momentum Stock Alerts - newser.com
Will Dianthus Therapeutics Inc. (87E) stock gain from green policies2025 Fundamental Recap & Consistent Profit Alerts - newser.com
Dianthus Therapeutics, Inc. (DNTH) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Using economic indicators to assess Dianthus Therapeutics Inc. potentialWeekly Gains Summary & Risk Managed Trade Strategies - newser.com
Dianthus Therapeutics (DNTH) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
What to expect from Dianthus Therapeutics Inc. in the next 30 daysJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
How to monitor Dianthus Therapeutics Inc. with trend dashboardsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Dianthus Therapeutics, Inc. (DNTH) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting - The Manila Times
Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026 - Quiver Quantitative
Dianthus (NASDAQ: DNTH) plans Phase 3 gMG with two claseprubart arms and QMG≥10 criterion - Stock Titan
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):